Forty six patients with lymphoid
malignancies receiving autologous transplants using three different sources of hematopoietic stem cells were compared for engraftment parameters. Thirteen patients (five with
multiple myeloma, seven with
non-Hodgkin's lymphoma and one with
Hodgkin's lymphoma) received autologous marrow with post-transplant
growth factors (group 1). During the same time interval, 14 patients (five with
multiple myeloma, six with
non-Hodgkin's lymphoma and three with
Hodgkin's lymphoma) were transplanted with autologous marrow plus recombinant
granulocyte colony-stimulating factor (rhG-CSF)-mobilized peripheral blood stem cells (PBSC) and post-transplant
growth factors (group 2). Nineteen patients (seven with
multiple myeloma and 12 with
non-Hodgkin's lymphoma) received rhG-CSF mobilized PBSC and post-transplant
growth factors (group 3). All PBSC were collected after
G-CSF mobilization (16 micrograms/kg/day s.c. for 6 days) without prior
chemotherapy. After high-dose myeloablative
chemotherapy or
chemoradiotherapy, the median days to recovery of neutrophils to levels of 0.5 and 1.0 x 10(9)/l were 12 vs. 9 vs. 9 days (P = 0.0003 (group 1 vs. group 2) and P = 0.53 (group 2 vs. group 3)) and 13 vs. 10 vs. 10 days (P = 0.0003 (group 1 vs. group 2) and 0.92 (group 2 vs. group 3)) for groups 1, 2 and 3, respectively. The median day to
platelet transfusion independence was 22 vs. 11 vs. 11 days (P = 0.001 (group 1 vs. group 2) and P = 0.50 (group 2 vs. group 3)) for groups 1, 2 and 3, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)